Chemokines in health and disease

Experimental Cell Research

Volumn 317, Issue 5, 2011, Pages 575-589

  Raman, Dayanidhi ^a   Sobolik Delmaire, Tammy ^a   Richmond, Ann ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; Chemokines; Leukocytes; Metastasis; Tumor progression

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR;

ANGIOGENESIS; AUTOIMMUNE DISEASE; BIOREACTOR; CANCER INVASION; CHEMOTAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; EMBRYO DEVELOPMENT; HUMAN; IMMUNITY; INFLAMMATION; LEUKOCYTE; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TUMOR; WOUND HEALING;

EID: 79952104164     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.01.005     Document Type: Review

References (219)

1. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
2. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., Power C.A. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52:145-176.
3. Neptune E.R., Bourne H.R. Receptors induce chemotaxis by releasing the betagamma subunit of Gi, not by activating Gq or Gs. Proc. Natl Acad. Sci. USA 1997, 94:14489-14494.
4. Neel, N. F. (2008). Regulation of CXC chemokine receptor function through intracellular trafficking and novel receptor-interacting proteins. Ph. D. Dissertation, Vanderbilt University.
5. Neel N.F., Barzik M., Raman D., Sobolik-Delmaire T., Sai J., Ham A.J., Mernaugh R.L., Gertler F.B., Richmond A. VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J. Cell Sci. 2009, 122:1882-1894.
6. Raman D., Neel N.F., Sai J., Mernaugh R.L., Ham A.J., Richmond A.J. Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse". Meth. Enzymol. 2009, 460:315-330.
7. Raman D., Sai J., Neel N.F., Chew C.S., Richmond A. LIM and SH3 protein-1 modulates CXCR2-mediated cell migration. PLoS ONE 2010, 5:e10050.
8. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., Parsons J.T., Horwitz A.R. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
9. Sohy D., Parmentier M., Springael J.Y. Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J. Biol. Chem. 2007, 282:30062-30069.
10. Sohy D., Yano H., de Nadai P., Urizar E., Guillabert A., Javitch J.A., Parmentier M., Springael J.Y. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J. Biol. Chem. 2009, 284:31270-31279.
11. Porcile C., Bajetto A., Barbero S., Pirani P., Schettini G. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann. NY Acad. Sci. 2004, 1030:162-169.
12. Porcile C., Bajetto A., Barbieri F., Barbero S., Bonavia R., Biglieri M., Pirani P., Florio T., Schettini G. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp. Cell Res. 2005, 308:241-253.
13. Majka M., Drukala J., Lesko E., Wysoczynski M., Jenson A.B., Ratajczak M.Z. SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells. Folia Histochem. Cytobiol. 2006, 44:155-164.
14. Wong M., Uddin S., Majchrzak B., Huynh T., Proudfoot A.E., Platanias L.C., Fish E.N. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J. Biol. Chem. 2001, 276:11427-11431.
15. Wong M.M., Fish E.N. Chemokines: attractive mediators of the immune response. Semin. Immunol. 2003, 15:5-14.
16. Sai J., Raman D., Liu Y., Wikswo J., Richmond A. Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis. J. Biol. Chem. 2008, 283:26538-26547.
17. Sai J., Walker G., Wikswo J., Richmond A. The IL sequence in the LLKIL motif in CXCR2 is required for full ligand-induced activation of Erk, Akt, and chemotaxis in HL60 cells. J. Biol. Chem. 2006, 281:35931-35941.
18. Even-Ram S., Yamada K.M. Cell migration in 3D matrix. Curr. Opin. Cell Biol. 2005, 17:524-532.
19. Fraley S.I., Feng Y., Krishnamurthy R., Kim D.H., Celedon A., Longmore G.D., Wirtz D. A distinctive role for focal adhesion proteins in three-dimensional cell motility. Nat. Cell Biol. 2010, 12:598-604.
20. Klemke M., Kramer E., Konstandin M.H., Wabnitz G.H., Samstag Y. An MEK-cofilin signalling module controls migration of human T cells in 3D but not 2D environments. EMBO J. 2010, 29:2915-2929.
21. Bonvin C., Overney J., Shieh A.C., Dixon J.B., Swartz M.A. A multichamber fluidic device for 3D cultures under interstitial flow with live imaging: development, characterization, and applications. Biotechnol. Bioeng. 2010, 105:982-991.
22. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7:211-224.
23. Choe M.M., Tomei A.A., Swartz M.A. Physiological 3D tissue model of the airway wall and mucosa. Nat. Protoc. 2006, 1:357-362.
24. Haessler U., Kalinin Y., Swartz M.A., Wu M. An agarose-based microfluidic platform with a gradient buffer for 3D chemotaxis studies. Biomed. Microdevices 2009, 11:827-835.
25. Pedersen J.A., Swartz M.A. Mechanobiology in the third dimension. Ann. Biomed. Eng. 2005, 33:1469-1490.
26. Poznansky M.C., Evans R.H., Foxall R.B., Olszak I.T., Piascik A.H., Hartman K.E., Brander C., Meyer T.H., Pykett M.J., Chabner K.T., Kalams S.A., Rosenzweig M., Scadden D.T. Efficient generation of human T cells from a tissue-engineered thymic organoid. Nat. Biotechnol. 2000, 18:729-734.
27. Tomei A.A., Siegert S., Britschgi M.R., Luther S.A., Swartz M.A. Fluid flow regulates stromal cell organization and CCL21 expression in a tissue-engineered lymph node microenvironment. J. Immunol. 2009, 183:4273-4283.
28. Shields J.D., Fleury M.E., Yong C., Tomei A.A., Randolph G.J., Swartz M.A. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007, 11:526-538.
29. Issa A., Le T.X., Shoushtari A.N., Shields J.D., Swartz M.A. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res. 2009, 69:349-357.
30. Hannan N.J., Salamonsen L.A. Role of chemokines in the endometrium and in embryo implantation. Curr. Opin. Obstet. Gynecol. 2007, 19:266-272.
31. Hannan N.J., Jones R.L., White C.A., Salamonsen L.A. The chemokines, CX3CL1, CCL14, and CCL4, promote human trophoblast migration at the feto-maternal interface. Biol. Reprod. 2006, 74:896-904.
32. Hess A.P., Hamilton A.E., Talbi S., Dosiou C., Nyegaard M., Nayak N., Genbecev-Krtolica O., Mavrogianis P., Ferrer K., Kruessel J., Fazleabas A.T., Fisher S.J., Giudice L.C. Decidual stromal cell response to paracrine signals from the trophoblast: amplification of immune and angiogenic modulators. Biol. Reprod. 2007, 76:102-117.
33. McGrath K.E., Koniski A.D., Maltby K.M., McGann J.K., Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev. Biol. 1999, 213:442-456.
34. Boldajipour B., Mahabaleshwar H., Kardash E., Reichman-Fried M., Blaser H., Minina S., Wilson D., Xu Q., Raz E. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008, 132:463-473.
35. Banisadr G., Fontanges P., Haour F., Kitabgi P., Rostene W., Melik Parsadaniantz S. Neuroanatomical distribution of CXCR4 in adult rat brain and its localization in cholinergic and dopaminergic neurons. Eur. J. Neurosci. 2002, 16:1661-1671.
36. Belmadani A., Tran P.B., Ren D., Assimacopoulos S., Grove E.A., Miller R.J. The chemokine stromal cell-derived factor-1 regulates the migration of sensory neuron progenitors. J. Neurosci. 2005, 25:3995-4003.
37. Stumm R.K., Rummel J., Junker V., Culmsee C., Pfeiffer M., Krieglstein J., Hollt V., Schulz S. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J. Neurosci. 2002, 22:5865-5878.
38. Stumm R., Hollt V. CXC chemokine receptor 4 regulates neuronal migration and axonal pathfinding in the developing nervous system: implications for neuronal regeneration in the adult brain. J. Mol. Endocrinol. 2007, 38:377-382.
39. Ohshima Y., Kubo T., Koyama R., Ueno M., Nakagawa M., Yamashita T. Regulation of axonal elongation and pathfinding from the entorhinal cortex to the dentate gyrus in the hippocampus by the chemokine stromal cell-derived factor 1 alpha. J. Neurosci. 2008, 28:8344-8353.
40. Bajetto A., Bonavia R., Barbero S., Florio T., Costa A., Schettini G. Expression of chemokine receptors in the rat brain. Ann. NY Acad. Sci. 1999, 876:201-209.
41. Li M., Ransohoff R.M. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog. Neurobiol. 2008, 84:116-131.
42. Sanchez-Sanchez A.V., Camp E., Leal-Tassias A., Atkinson S.P., Armstrong L., Diaz-Llopis M., Mullor J.L. Nanog regulates primordial germ cell migration through Cxcr4b. Stem Cells 2010, 28:1457-1464.
43. Tsai H.H., Frost E., To V., Robinson S., Ffrench-Constant C., Geertman R., Ransohoff R.M., Miller R.H. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002, 110:373-383.
44. Lopez-Bendito G., Sanchez-Alcaniz J.A., Pla R., Borrell V., Pico E., Valdeolmillos M., Marin O. Chemokine signaling controls intracortical migration and final distribution of GABAergic interneurons. J. Neurosci. 2008, 28:1613-1624.
45. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
46. Vasyutina E., Stebler J., Brand-Saberi B., Schulz S., Raz E., Birchmeier C. CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells. Genes Dev. 2005, 19:2187-2198.
47. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680.
48. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
49. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
50. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
51. McDonald B., Pittman K., Menezes G.B., Hirota S.A., Slaba I., Waterhouse C.C., Beck P.L., Muruve D.A., Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366.
52. Esche C., Stellato C., Beck L.A. Chemokines: key players in innate and adaptive immunity. J. Invest. Dermatol. 2005, 125:615-628.
53. Grigorova I.L., Schwab S.R., Phan T.G., Pham T.H., Okada T., Cyster J.G. Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells. Nat. Immunol. 2009, 10:58-65.
54. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
55. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat. Rev. Immunol. 2009, 9:618-629.
56. Weninger W., von Andrian U.H. Chemokine regulation of naive T cell traffic in health and disease. Semin. Immunol. 2003, 15:257-270.
57. Han C., Jin J., Xu S., Liu H., Li N., Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat. Immunol. 2010, 11:734-742.
58. West X.Z., Malinin N.L., Merkulova A.A., Tischenko M., Kerr B.A., Borden E.C., Podrez E.A., Salomon R.G., Byzova T.V. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010, 467:972-976.
59. Zaja-Milatovic S., Richmond A. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol. Histopathol. 2008, 23:1399-1407.
60. Gillitzer R., Goebeler M. Chemokines in cutaneous wound healing. J. Leukoc. Biol. 2001, 69:513-521.
61. Nanney L.B., Mueller S.G., Bueno R., Peiper S.C., Richmond A. Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair. Am. J. Pathol. 1995, 147:1248-1260.
62. Devalaraja R.M., Nanney L.B., Du J., Qian Q., Yu Y., Devalaraja M.N., Richmond A. Delayed wound healing in CXCR2 knockout mice. J. Invest. Dermatol. 2000, 115:234-244.
63. Luster A.D., Cardiff R.D., MacLean J.A., Crowe K., Granstein R.D. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc. Assoc. Am. Physicians 1998, 110:183-196.
64. Ishida Y., Gao J.L., Murphy P.M. Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function. J. Immunol. 2008, 180:569-579.
65. Inokuma D., Abe R., Fujita Y., Sasaki M., Shibaki A., Nakamura H., McMillan J.R., Shimizu T., Shimizu H. CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes. Stem Cells 2006, 24:2810-2816.
66. Schneider D.F., Palmer J.L., Tulley J.M., Kovacs E.J., Gamelli R.L., Faunce D.E. Prevention of NKT cell activation accelerates cutaneous wound closure and alters local inflammatory signals. J. Surg. Res. 2010.
67. Thuraisingam T., Xu Y.Z., Eadie K., Heravi M., Guiot M.C., Greemberg R., Gaestel M., Radzioch D. MAPKAPK-2 signaling is critical for cutaneous wound healing. J Invest Dermatol 2010, 130:278-286.
68. Belperio J.A., Keane M.P., Arenberg D.A., Addison C.L., Ehlert J.E., Burdick M.D., Strieter R.M. CXC chemokines in angiogenesis. J. Leukoc. Biol. 2000, 68:1-8.
69. Keane M.P., Arenberg D.A., Moore B.B., Addison C.L., Strieter R.M. CXC chemokines and angiogenesis/angiostasis. Proc. Assoc. Am. Physicians 1998, 110:288-296.
70. Mehrad B., Keane M.P., Strieter R.M. Chemokines as mediators of angiogenesis. Thromb. Haemost. 2007, 97:755-762.
71. Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:593-609.
72. Strieter R.M., Polverini P.J., Arenberg D.A., Kunkel S.L. The role of CXC chemokines as regulators of angiogenesis. Shock 1995, 4:155-160.
73. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., Dzuiba J., Van Damme J., Walz A., Marriott D., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995, 270:27348-27357.
74. Yang J., Richmond A. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 2004, 9:846-855.
75. Du J., Luan J., Liu H., Daniel T.O., Peiper S., Chen T.S., Yu Y., Horton L.W., Nanney L.B., Strieter R.M., Richmond A. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J. Leukoc. Biol. 2002, 71:141-153.
76. Horton L.W., Yu Y., Zaja-Milatovic S., Strieter R.M., Richmond A. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res. 2007, 67:9791-9799.
77. + CXC chemokine-induced angiogenic activity. J. Immunol. 2000, 165:5269-5277.
78. Murdoch C., Monk P.N., Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999, 11:704-712.
79. Heidemann J., Ogawa H., Dwinell M.B., Rafiee P., Maaser C., Gockel H.R., Otterson M.F., Ota D.M., Lugering N., Domschke W., Binion D.G. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 2003, 278:8508-8515.
80. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 1996, 97:2792-2802.
81. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., Fidler I.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl Cancer Inst. 1998, 90:447-454.
82. Luan J., Shattuck-Brandt R., Haghnegahdar H., Owen J.D., Strieter R., Burdick M., Nirodi C., Beauchamp D., Johnson K.N., Richmond A. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J. Leukoc. Biol. 1997, 62:588-597.
83. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1928-1936.
84. + endothelial cells. J. Immunol. 2001, 166:7571-7578.
85. Strasly M., Doronzo G., Capello P., Valdembri D., Arese M., Mitola S., Moore P., Alessandri G., Giovarelli M., Bussolino F. CCL16 activates an angiogenic program in vascular endothelial cells. Blood 2004, 103:40-49.
86. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
87. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007, 67:10019-10026.
88. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
89. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010, 21:27-39.
90. Wang D., Dubois R.N., Richmond A. The role of chemokines in intestinal inflammation and cancer. Curr. Opin. Pharmacol. 2009, 9:688-696.
91. + myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
92. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., Weinrauch Y., Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
93. Marcos V., Zhou Z., Yildirim A.O., Bohla A., Hector A., Vitkov L., Wiedenbauer E.M., Krautgartner W.D., Stoiber W., Belohradsky B.H., Rieber N., Kormann M., Koller B., Roscher A., Roos D., Griese M., Eickelberg O., Doring G., Mall M.A., Hartl D. CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat. Med. 2010, 16:1018-1023.
94. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010, 16:133-144.
95. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
96. Talmadge J.E., Donkor M., Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007, 26:373-400.
97. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256:137-165.
98. Mantovani A., Sica A., Allavena P., Garlanda C., Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 2009, 70:325-330.
99. Grohmann U., Fallarino F., Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003, 24:242-248.
100. Youn J.I., Gabrilovich D.I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 2010, 40:2969-2975.
101. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
102. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., O'Malley K.A., Wynn J.L., Antonenko S., Al-Quran S.Z., Swan R., Chung C.S., Atkinson M.A., Ramphal R., Gabrilovich D.I., Reeves W.H., Ayala A., Phillips J., Laface D., Heyworth P.G., Clare-Salzler M., Moldawer L.L. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007, 204:1463-1474.
103. + myeloid cells. Cancer Res. 2006, 66:6807-6815.
104. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
105. + T cells. J. Clin. Invest. 2006, 116:2777-2790.
106. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838-3846.
107. + myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010, 70:6139-6149.
108. Rafii S., Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat. Cell Biol. 2006, 8:1321-1323.
109. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8:1369-1375.
110. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 2008, 181:4666-4675.
111. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., Ortiz M., Nacken W., Sorg C., Vogl T., Roth J., Gabrilovich D.I. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205:2235-2249.
112. Richmond A. Chemokine modulation of the tumor microenvironment. Pigment Cell Melanoma Res. 2010, 23:312-313.
113. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
114. Ugel S., Delpozzo F., Desantis G., Papalini F., Simonato F., Sonda N., Zilio S., Bronte V. Therapeutic targeting of myeloid-derived suppressor cells. Curr. Opin. Pharmacol. 2009, 9:470-481.
115. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 2010, 59:1593-1600.
116. Winfield R.D., Delano M.J., Pande K., Scumpia P.O., Laface D., Moldawer L.L. Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. JPEN J. Parenter. Enteral Nutr. 2008, 32:651-655.
117. Summers C., Rankin S.M., Condliffe A.M., Singh N., Peters A.M., Chilvers E.R. Neutrophil kinetics in health and disease. Trends Immunol. 2010, 31:318-324.
118. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G.S., Albelda S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
119. Cheong C., Matos I., Choi J.H., Dandamudi D.B., Shrestha E., Longhi M.P., Jeffrey K.L., Anthony R.M., Kluger C., Nchinda G., Koh H., Rodriguez A., Idoyaga J., Pack M., Velinzon K., Park C.G., Steinman R.M. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 2010, 143:416-429.
120. Saccheri F., Pozzi C., Avogadri F., Barozzi S., Faretta M., Fusi P., Rescigno M. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci. Transl. Med. 2010, 2:44ra57.
121. Kleeff J., Kusama T., Rossi D.L., Ishiwata T., Maruyama H., Friess H., Buchler M.W., Zlotnik A., Korc M. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 1999, 81:650-657.
122. Scarpino S., Stoppacciaro A., Ballerini F., Marchesi M., Prat M., Stella M.C., Sozzani S., Allavena P., Mantovani A., Ruco L.P. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 2000, 156:831-837.
123. Vicari A.P., Treilleux I., Lebecque S. Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin. Cancer Biol. 2004, 14:161-169.
124. Fushimi T., Kojima A., Moore M.A., Crystal R.G. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 2000, 105:1383-1393.
125. Bell D., Chomarat P., Broyles D., Netto G., Harb G.M., Lebecque S., Valladeau J., Davoust J., Palucka K.A., Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 1999, 190:1417-1426.
126. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., Wei S., Krzysiek R., Durand-Gasselin I., Gordon A., Pustilnik T., Curiel D.T., Galanaud P., Capron F., Emilie D., Curiel T.J. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 2001, 7:1339-1346.
127. Treilleux I., Blay J.Y., Bendriss-Vermare N., Ray-Coquard I., Bachelot T., Guastalla J.P., Bremond A., Goddard S., Pin J.J., Barthelemy-Dubois C., Lebecque S. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 2004, 10:7466-7474.
128. Ma Y., Aymeric L., Locher C., Kroemer G., Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr. Opin. Immunol. 2010, [Epub ahead of print].
129. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., Jove R., Pardoll D., Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
130. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., Biota C., Doffin A.C., Durand I., Olive D., Perez S., Pasqual N., Faure C., Ray-Coquard I., Puisieux A., Caux C., Blay J.Y., Menetrier-Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69:2000-2009.
131. Villablanca E.J., Raccosta L., Zhou D., Fontana R., Maggioni D., Negro A., Sanvito F., Ponzoni M., Valentinis B., Bregni M., Prinetti A., Steffensen K.R., Sonnino S., Gustafsson J.A., Doglioni C., Bordignon C., Traversari C., Russo V. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 2010, 16:98-105.
132. Semmling V., Lukacs-Kornek V., Thaiss C.A., Quast T., Hochheiser K., Panzer U., Rossjohn J., Perlmutter P., Cao J., Godfrey D.I., Savage P.B., Knolle P.A., Kolanus W., Forster I., Kurts C. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat. Immunol. 2010, 11:313-320.
133. Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M.A., Vallejo C., Martos J.A., Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79:2320-2328.
134. Takanami I., Takeuchi K., Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J. Thorac. Cardiovasc. Surg. 2001, 121:1058-1063.
135. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Che X., Iwashige H., Aridome K., Hokita S., Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000, 88:577-583.
136. Villegas F.R., Coca S., Villarrubia V.G., Jimenez R., Chillon M.J., Jareno J., Zuil M., Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002, 35:23-28.
137. Maghazachi A.A. Role of chemokines in the biology of natural killer cells. Curr. Top. Microbiol. Immunol. 2010, 341:37-58.
138. Wendel M., Galani I.E., Suri-Payer E., Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008, 68:8437-8445.
139. + T cells and natural killer cells in gastric adenocarcinoma. Ann. Surg. Oncol. 2008, 15:1775-1782.
140. Lavergne E., Combadiere B., Bonduelle O., Iga M., Gao J.L., Maho M., Boissonnas A., Murphy P.M., Debre P., Combadiere C. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res. 2003, 63:7468-7474.
141. Liu C., Lou Y., Lizee G., Qin H., Liu S., Rabinovich B., Kim G.J., Wang Y.H., Ye Y., Sikora A.G., Overwijk W.W., Liu Y.J., Wang G., Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J. Clin. Invest. 2008, 118:1165-1175.
142. + T cells in lymphocyte-rich gastric carcinoma. J. Pathol. 2009, 217:21-31.
143. Ludwig A., Schulte A., Schnack C., Hundhausen C., Reiss K., Brodway N., Held-Feindt J., Mentlein R. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J. Neurochem. 2005, 93:1293-1303.
144. Ohta M., Tanaka F., Yamaguchi H., Sadanaga N., Inoue H., Mori M. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int. J. Oncol. 2005, 26:41-47.
145. Matsumura S., Wang B., Kawashima N., Braunstein S., Badura M., Cameron T.O., Babb J.S., Schneider R.J., Formenti S.C., Dustin M.L., Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 2008, 181:3099-3107.
146. + T cells. Immunity 2005, 22:371-383.
147. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000, 12:677-686.
148. +) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
149. Mailloux A.W., Young M.R. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J. Immunol. 2009, 182:2753-2765.
150. Oble D.A., Loewe R., Yu P., Mihm M.C. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009, 9:3.
151. de Visser K.E., Korets L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005, 7:411-423.
152. Ammirante M., Luo J.L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305.
153. Tan W., Martin D., Gutkind J.S. The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J. Biol. Chem. 2006, 281:39542-39549.
154. Zhao M., Mueller B.M., DiScipio R.G., Schraufstatter I.U. Akt plays an important role in breast cancer cell chemotaxis to CXCL12. Breast Cancer Res. Treat. 2008, 110:211-222.
155. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
156. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
157. Liang Z., Wu T., Lou H., Yu X., Taichman R.S., Lau S.K., Nie S., Umbreit J., Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 2004, 64:4302-4308.
158. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005, 65:967-971.
159. Bajetto A., Barbieri F., Dorcaratto A., Barbero S., Daga A., Porcile C., Ravetti J.L., Zona G., Spaziante R., Corte G., Schettini G., Florio T. Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration. Neurochem. Int. 2006, 49:423-432.
160. Ehtesham M., Mapara K.Y., Stevenson C.B., Thompson R.C. CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett. 2009, 274:305-312.
161. Rempel S.A., Dudas S., Ge S., Gutierrez J.A. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin. Cancer Res. 2000, 6:102-111.
162. Zhou Y., Larsen P.H., Hao C., Yong V.W. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J. Biol. Chem. 2002, 277:49481-49487.
163. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
164. Hermann P.C., Mueller M.T., Heeschen C. Pancreatic cancer stem cells-insights and perspectives. Expert Opin. Biol. Ther. 2009, 9:1271-1278.
165. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., Zhou X., Xia W., Hortobagyi G.N., Yu D., Hung M.C. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6:459-469.
166. Chinni S.R., Yamamoto H., Dong Z., Sabbota A., Bonfil R.D., Cher M.L. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res. 2008, 6:446-457.
167. Cabioglu N., Summy J., Miller C., Parikh N.U., Sahin A.A., Tuzlali S., Pumiglia K., Gallick G.E., Price J.E. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res. 2005, 65:6493-6497.
168. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
169. Miao Z., Luker K.E., Summers B.C., Berahovich R., Bhojani M.S., Rehemtulla A., Kleer C.G., Essner J.J., Nasevicius A., Luker G.D., Howard M.C., Schall T.J. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl Acad. Sci. USA 2007, 104:15735-15740.
170. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K.J., Mehra R., Loberg R., Taichman R.S. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 2008, 283:4283-4294.
171. Iwakiri S., Mino N., Takahashi T., Sonobe M., Nagai S., Okubo K., Wada H., Date H., Miyahara R. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009, 115:2580-2593.
172. Amiri K.I., Ha H.C., Smulson M.E., Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene 2006, 25:7714-7722.
173. Dhawan P., Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 2002, 72:9-18.
174. Nirodi C., NagDas S., Gygi S.P., Olson G., Aebersold R., Richmond A. A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J. Biol. Chem. 2001, 276:9366-9374.
175. Varney M.L., Johansson S.L., Singh R.K. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 2006, 125:209-216.
176. Singh S., Nannuru K.C., Sadanandam A., Varney M.L., Singh R.K. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br. J. Cancer 2009, 100:1638-1646.
177. Letsch A., Keilholz U., Schadendorf D., Assfalg G., Asemissen A.M., Thiel E., Scheibenbogen C. Functional CCR9 expression is associated with small intestinal metastasis. J. Invest. Dermatol. 2004, 122:685-690.
178. Amersi F.F., Terando A.M., Goto Y., Scolyer R.A., Thompson J.F., Tran A.N., Faries M.B., Morton D.L., Hoon D.S. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin. Cancer Res. 2008, 14:638-645.
179. Richmond A. CCR9 homes metastatic melanoma cells to the small bowel. Clin. Cancer Res. 2008, 14:621-623.
180. Simonetti O., Goteri G., Lucarini G., Filosa A., Pieramici T., Rubini C., Biagini G., Offidani A. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur. J. Cancer 2006, 42:1181-1187.
181. Mashino K., Sadanaga N., Yamaguchi H., Tanaka F., Ohta M., Shibuta K., Inoue H., Mori M. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002, 62:2937-2941.
182. Ding Y., Shimada Y., Maeda M., Kawabe A., Kaganoi J., Komoto I., Hashimoto Y., Miyake M., Hashida H., Imamura M. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 2003, 9:3406-3412.
183. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int. J. Cancer 2003, 105:186-189.
184. Gunther K., Leier J., Henning G., Dimmler A., Weissbach R., Hohenberger W., Forster R. Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int. J. Cancer 2005, 116:726-733.
185. Eisenhardt A., Frey U., Tack M., Rosskopf D., Lümmen G., Rübben H., Siffert W. Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur. Urol. 2005, 47:111-117.
186. Retz M.M., Sidhu S.S., Blaveri E., Kerr S.C., Dolganov G.M., Lehmann J., Carroll P., Simko J., Waldman F.M., Basbaum C. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int. J. Cancer 2005, 114:182-189.
187. Ghadjar P., Coupland S.E., Na I.K., Noutsias M., Letsch A., Stroux A., Bauer S., Buhr H.J., Thiel E., Scheibenbogen C., Keilholz U. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J. Clin. Oncol. 2006, 24:1910-1916.
188. Rubie C., Frick V.O., Ghadjar P., Wagner M., Grimm H., Vicinus B., Justinger C., Graeber S., Schilling M.K. CCL20/CCR6 expression profile in pancreatic cancer. J. Transl. Med. 2010, 8:45.
189. Ghadjar P., Loddenkemper C., Coupland S.E., Stroux A., Noutsias M., Thiel E., Christoph F., Miller K., Scheibenbogen C., Keilholz U. Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J. Cancer Res. Clin. Oncol. 2008, 134:1181-1189.
190. Ma X., Norsworthy K., Kundu N., Rodgers W.H., Gimotty P.A., Goloubeva O., Lipsky M., Li Y., Holt D., Fulton A. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol. Cancer Ther. 2009, 8:490-498.
191. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25:315-322.
192. Sozzani S., Rusnati M., Riboldi E., Mitola S., Presta M. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol. 2007, 28:385-392.
193. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
194. Hansell C.A., Simpson C.V., Nibbs R.J. Chemokine sequestration by atypical chemokine receptors. Biochem. Soc. Trans. 2006, 34:1009-1013.
195. Wu F.Y., Ou Z.L., Feng L.Y., Luo J.M., Wang L.P., Shen Z.Z., Shao Z.M. Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol. Cancer Res. 2008, 6:1276-1288.
196. Pruenster M., Mudde L., Bombosi P., Dimitrova S., Zsak M., Middleton J., Richmond A., Graham G.J., Segerer S., Nibbs R.J., Rot A. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat. Immunol. 2009, 10:101-108.
197. Szekanecz Z., Vegvari A., Szabo Z., Koch A.E. Chemokines and chemokine receptors in arthritis. Front. Biosci. (Schol Ed) 2009, 2:153-167.
198. Isaacs J.D. The changing face of rheumatoid arthritis: sustained remission for all?. Nat. Rev. Immunol. 2010, 10:605-611.
199. Szekanecz Z., Strieter R.M., Kunkel S.L., Koch A.E. Chemokines in rheumatoid arthritis. Springer Semin. Immunopathol. 1998, 20:115-132.
200. Szekanecz Z., Koch A.E. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 2007, 19:289-295.
201. De Gendt C.M., De Clerck L.S., Bridts C.H., Van Osselaer N., Stevens W.J. Relationship between interleukin-8 and neutrophil adhesion molecules in rheumatoid arthritis. Rheumatol. Int. 1996, 16:169-173.
202. Seitz M., Dewald B., Ceska M., Gerber N., Baggiolini M. Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol. Int. 1992, 12:159-164.
203. Szekanecz Z., Pakozdi A., Szentpetery A., Besenyei T., Koch A.E. Chemokines and angiogenesis in rheumatoid arthritis. Front. Biosci. (Elite Ed) 2009, 1:44-51.
204. Berckmans R.J., Nieuwland R., Kraan M.C., Schaap M.C., Pots D., Smeets T.J., Sturk A., Tak P.P. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res. Ther. 2005, 7:R536-R544.
205. Reich N., Beyer C., Gelse K., Akhmetshina A., Dees C., Zwerina J., Schett G., Distler O., Distler J.H. Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J. Cell. Mol. Med. 2010, [Epub ahead of print].
206. Distler J.H., Distler O. Inflammation: microparticles and their roles in inflammatory arthritides. Nat. Rev. Rheumatol. 2010, 6:385-386.
207. Manzo A., Paoletti S., Carulli M., Blades M.C., Barone F., Yanni G., Fitzgerald O., Bresnihan B., Caporali R., Montecucco C., Uguccioni M., Pitzalis C. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur. J. Immunol. 2005, 35:1347-1359.
208. Loetscher P., Moser B. Homing chemokines in rheumatoid arthritis. Arthritis Res. 2002, 4:233-236.
209. Nanki T., Shimaoka T., Hayashida K., Taniguchi K., Yonehara S., Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 2005, 52:3004-3014.
210. Ruth J.H., Haas C.S., Park C.C., Amin M.A., Martinez R.J., Haines G.K., Shahrara S., Campbell P.L., Koch A.E. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 2006, 54:765-778.
211. Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev. 2004, 56:515-548.
212. Barnes P.J. The cytokine network in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2009, 41:631-638.
213. Larsson K. Inflammatory markers in COPD. Clin. Respir. J. 2008, 2(Suppl 1):84-87.
214. Traves S.L., Donnelly L.E. Th17 cells in airway diseases. Curr. Mol. Med. 2008, 8:416-426.
215. Williams T.J., Jose P.J. Neutrophils in chronic obstructive pulmonary disease. Novartis Found. Symp. 2001, 234:136-141. discussion 141-8.
216. Bracke K.R., Demedts I.K., Joos G.F., Brusselle G.G. CC-chemokine receptors in chronic obstructive pulmonary disease. Inflamm. Allergy Drug Targets 2007, 6:75-79.
217. Barnes P.J. Frontrunners in novel pharmacotherapy of COPD. Curr. Opin. Pharmacol. 2008, 8:300-307.
218. Snelgrove R.J., Jackson P.L., Hardison M.T., Noerager B.D., Kinloch A., Gaggar A., Shastry S., Rowe S.M., Shim Y.M., Hussell T., Blalock J.E. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010, 330:90-94.
219. Galzi J.L., Hachet-Haas M., Bonnet D., Daubeuf F., Lecat S., Hibert M., Haiech J., Frossard N. Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications. Pharmacol. Ther. 2010, 126:39-55.